Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L8KJ
|
|||
Former ID |
DIB002837
|
|||
Drug Name |
Oglemilast
|
|||
Synonyms |
GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
Company |
Glenmark Pharmaceuticals Ltd
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H13Cl2F2N3O5S
|
|||
Canonical SMILES |
CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F
|
|||
InChI |
1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)
|
|||
InChIKey |
OKFDRAHPFKMAJH-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 778576-62-8
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
KEGG Pathway | Purine metabolism | |||
cAMP signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Pathwhiz Pathway | Purine Metabolism | |||
Reactome | DARPP-32 events | |||
G alpha (s) signalling events | ||||
WikiPathways | G Protein Signaling Pathways | |||
Myometrial Relaxation and Contraction Pathways | ||||
Nuclear Receptors Meta-Pathway | ||||
Opioid Signalling | ||||
TSH signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00671073) Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S. National Institutes of Health. | |||
REF 2 | Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.